Epidemiological review of confirmed Lassa fever cases during 2016-2018, in Plateau State, North Central Nigeria.

Lassa fever (LF) is endemic in West Africa and constitutes a significant public health concern due to its potential for epidemics and associated high mortality. The first reported case and management of Lassa fever in Plateau State occurred more than 50 years ago. We set out to undertake a three-year epidemiological review of LF cases in Plateau State, North Central Nigeria.

Human Monkey Pox Virus Infection in Plateau State, North Central Nigeria: A Report of Two Cases.

Background: Human Monkey Pox Virus (HMPV) infection is a zoonotic infection that is endemic in the Congo basin and West Africa. Its similarity to smallpox infection, increased susceptibility infection in human populations, lack of a definitive therapy and its potential for use as a bioterrorism tool underscores its public health importance.

Objective: To describe the characteristics of HMPV infection in Plateau State, North Central Nigeria.

A standardised Phase III clinical trial framework to assess therapeutic interventions for Lassa fever.

Background: Only one recommendation currently exists for the treatment of Lassa fever (LF), which is ribavirin administered in conjunction with supportive care. This recommendation is primarily based on evidence generated from a single clinical trial that was conducted more than 30 years ago-the methodology and results of which have recently come under scrutiny. The requirement for novel therapeutics and reassessment of ribavirin is therefore urgent.